Articles related to Cardiology, Interventional

Exploring the Korean National Health Insurance claims database revealed that rhythm control via ablation or drugs, initiated within 1 year of diagnosis of AF, was associated with lower risk for cardiovascular events. This held true for both low risk and higher risk patients. The study analyzed data on more than 35,000 patients with a median age of 70.

In a prospective study following the diet and activity records of more than 100,000 individuals in France, artificial sweeteners were positively correlated with cardiovascular diseases. Analyzing 900,000 person-years of data showed: Total artificial sweetener intake was associated with CVD risk Artificial sweeteners were more strongly associated with cerebrovascular disease Aspartame was associated with increase cerebrovascular events Acesulfame K and sucralose were associated with increased coronary heart disease risk

These recommendations “attempt to provide practical guidance for clinicians and patients regarding the use of nonstatin therapies to further reduce ASCVD risk in situations not covered by the guideline until such time as the scientific evidence base expands.”

Questions run across a host of topics, and in September you can challenge yourself in mortality risk, myocardial infarction (MI), insomnia, liver cancer, lipids, and Parkinson’s disease guidelines. Each question is worth 4 points with bonuses for quick response. Speed matters in this quiz. Why not give it a try and see if you can get on the leaderboard of the Smartest Doc?

To assess short-term risk for severe cardiovascular events (excluding myocarditis and pericarditis) after COVID-19 vaccination, adults younger than 75 years hospitalized for PE, acute MI, hemorrhagic stroke, or ischemic stroke (73,325 events) were reviewed in relation to a 1st or 2nd COVID vaccine dose. No association was found between the Pfizer–BioNTech or Moderna vaccine and severe cardiovascular events. The first dose of the Oxford–AstraZeneca vaccine was associated with acute MI and PE in the second week after vaccination. An association with MI in the second week after a single dose of the Janssen vaccine could not be ruled out.

The USPSTF comes to the conclusion that statin use has at least a moderate net benefit for adults aged 40 to 75 who have no prior history of CVD, at least one CVD risk factor, and an estimated 10-year CVD event risk of 10% or greater. There is at least a marginal net benefit from using statins to prevent CVD events and all-cause mortality in adults aged 40 to 75 who have no prior history of CVD, at least one of these risk factors, and an estimated 10-year CVD event risk of 7.5% to less than 10%. Still, is the evidence enough?